Has Roya Karbakhsh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,922 in general payments to Roya Karbakhsh, MD across 145 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roya Karbakhsh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roya Karbakhsh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roya Karbakhsh, MD

Child & Adolescent Psychiatry · Scottsdale, AZNPI 1992905293

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 26.2% of the total.

$5,922in general payments, 2019–2025

Across 145 payments — averaging $40.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$2K
AbbVie$1K
Lundbeck LLC$652
Corium, LLC$597
Takeda Pharmaceuticals U.S.A., Inc.$496
Johnson & Johnson$372
plus $1K from 14 others

What the payments were for

Food & beverage$5,922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	41	$1,551
AbbVie(2 entities)	21	$1,019
Lundbeck LLC	24	$652
Corium, LLC	10	$597
Takeda Pharmaceuticals U.S.A., Inc.	18	$496
Johnson & Johnson	8	$372
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$216
Neurocrine Biosciences, Inc.	2	$142
Teva Pharmaceuticals USA, Inc.	5	$132
Idorsia Pharmaceuticals US Inc	2	$129
E.r. Squibb & Sons, L.L.C.	1	$122
Axsome Therapeutics, Inc.	1	$122
UCB, Inc.	1	$109
Alkermes, Inc.	1	$98
Sunovion Pharmaceuticals Inc.	2	$52
Alfasigma USA, Inc.	2	$30
Arbor Pharmaceuticals, Inc.	1	$26
Supernus Pharmaceuticals, Inc.	1	$26
Shire North American Group Inc	1	$17
Lilly USA, LLC	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,922 in reported general payments places this provider in the 85th percentile of 80 child & adolescent psychiatry providers in Arizona.

See all child & adolescent psychiatry providers in Arizona →

Medicare billing

Part B allowed, 2024

$73,031

Medicare patients

Services billed

711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buspirone Hcl	65	$987
Mirtazapine	33	$943
Gabapentin	56	$900
Venlafaxine Hcl ErVenlafaxine Hcl	28	$815
Dextroamphetamine Sulfate	11	$692
Lamotrigine	43	$682
Escitalopram Oxalate	34	$520
Clonazepam	53	$506
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	24	$357
Zolpidem Tartrate	21	$351
Duloxetine Hcl	12	$346
Sertraline Hcl	18	$288
Bupropion Hcl SrBupropion Hcl	12	$254
Trazodone Hcl	36	$247
Alprazolam ErAlprazolam	24	$227

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Scottsdale

Ramiro GuillenScottsdale$31K
Linda KalivasScottsdale$13K
Palpu HazelScottsdale$13K
Kenneth ZwierScottsdale$7K
Fariba PfitznerScottsdale$5K
Shaili PatelScottsdale$3K
Marilyn Pupo GuillenScottsdale$2K
Lilia Romero-BoschScottsdale$1K
Patricia Tagle-LevyScottsdale$732
Sandeep KaurScottsdale$626

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →